Published in Cancer Treat Rep on June 01, 1978
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer (2010) 2.25
Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation (2008) 1.61
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal (2012) 1.37
Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc (2004) 1.32
Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J (2009) 1.28
Mitral regurgitation after anthracycline treatment for childhood malignancy. Heart (2001) 1.10
Doxorubicin (adriamycin) cardiomyopathy. West J Med (1983) 1.01
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br J Cancer (2007) 0.95
Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest (1993) 0.94
Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol (1980) 0.94
Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med (1979) 0.93
A mouse model for juvenile doxorubicin-induced cardiac dysfunction. Pediatr Res (2008) 0.92
RGS Proteins in Heart: Brakes on the Vagus. Front Physiol (2012) 0.86
The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart Vessels (2007) 0.86
Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child (1994) 0.85
P53 inhibition exacerbates late-stage anthracycline cardiotoxicity. Cardiovasc Res (2014) 0.83
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Support Care Cancer (2005) 0.83
Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. Eur J Pediatr (2005) 0.83
Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Mol Imaging (2009) 0.82
Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial - A Prospective Randomized Study. Korean Circ J (2013) 0.79
Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. Mol Cell Pharmacol (2010) 0.79
Anthracycline-induced cardiomyopathy. Postgrad Med J (1999) 0.79
Intra-arterial adriamycin chemotherapy for bladder cancer. Semiselective intra-arterial chemotherapy with compression of the femoral arteries at the time of injection. Cancer Chemother Pharmacol (1983) 0.79
Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. Am Heart J (2012) 0.77
Targeted ultrasound imaging of apoptosis with annexin a5 microbubbles in acute Doxorubicin-induced cardiotoxicity. J Cardiovasc Ultrasound (2010) 0.76
The role of cell death and myofibrillar damage in contractile dysfunction of long-term cultured adult cardiomyocytes exposed to doxorubicin. Cytotechnology (2009) 0.76
Multifunctional protein: cardiac ankyrin repeat protein. J Zhejiang Univ Sci B (2016) 0.75
Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity. Iran J Basic Med Sci (2015) 0.75
Daunorubicin, amsacrine, and sinus arrest. West J Med (1991) 0.75
Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts). Indian J Anaesth (2009) 0.75
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 6.79
A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med (1995) 6.14
Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol (1987) 5.33
Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med (1982) 4.40
Acrasin, Acrasinase, and the sensitivity to acrasin in Dictyostelium discoideum. Dev Biol (1969) 3.56
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation (1999) 3.35
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol (1995) 3.12
Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet (1993) 3.10
Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res (2000) 3.08
Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep (1978) 2.63
Degradation of collagen by a human granulocyte collagenolytic system. J Clin Invest (1968) 2.62
Congestive heart failure: fifty years of progress. Circulation (2000) 2.61
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med (1993) 2.39
Myosin heavy chain gene expression in human heart failure. J Clin Invest (1997) 2.39
Low urinary cortisol excretion in Holocaust survivors with posttraumatic stress disorder. Am J Psychiatry (1995) 2.39
Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant (1994) 2.36
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation (1983) 2.24
Some recent advances in cardiac pathology. Hum Pathol (1979) 2.17
Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol (1980) 2.17
Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest (1992) 2.07
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Amiodarone. N Engl J Med (1987) 2.05
Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum (2000) 2.01
Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation (1996) 2.01
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation (1997) 2.00
Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation (1986) 1.97
Advances in the understanding of myocarditis. Circulation (2001) 1.93
Role of granulocyte collagenase in collagen degradation. Am J Pathol (1972) 1.92
Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant (1990) 1.91
Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest (1984) 1.91
Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther (1983) 1.90
Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation (1996) 1.86
Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest (1988) 1.85
Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation (1997) 1.84
Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J Thorac Cardiovasc Surg (1973) 1.82
Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med (1983) 1.81
Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation (1997) 1.81
Deficits in short-term memory in posttraumatic stress disorder. Am J Psychiatry (1993) 1.81
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol (1991) 1.81
Transesophageal echocardiography and its potential for esophageal damage. Anesthesiology (1990) 1.80
Cardiac transplant atherosclerosis. Transplant Proc (1987) 1.74
Injectable collagen for soft tissue augmentation. Plast Reconstr Surg (1977) 1.70
Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol (2001) 1.70
Techniques for right and left ventricular endomyocardial biopsy. Am J Cardiol (1978) 1.68
Human granulocyte collagenase. Science (1968) 1.68
A review of psychoendocrine research on the pituitary-adrenal cortical system. Psychosom Med (1969) 1.65
The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev (1998) 1.63
Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis (1990) 1.63
Early anthracycline cardiotoxicity. Am J Med (1978) 1.63
Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A (1990) 1.59
Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry (1993) 1.56
Plasma kallikrein and Hageman factor in Gram-negative bacteremia. Ann Intern Med (1970) 1.53
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol (1998) 1.53
Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol (1996) 1.52
Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. Biol Psychiatry (1991) 1.52
Endocardial infiltrates in human heart transplants: a serial biopsy analysis comparing four immunosuppression protocols. Hum Pathol (1990) 1.50
Evaluation of heart-lung transplant recipients with prospective, serial transbronchial biopsies and pulmonary function studies. J Thorac Cardiovasc Surg (1989) 1.49
Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Electrophysiologic Study Versus Electromagnetic Monitoring. Circulation (1997) 1.49
Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet (1991) 1.49
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med (1992) 1.48
Prevalence of infection following hepatic chemoembolization with cross-linked collagen with administration of prophylactic antibiotics. J Vasc Interv Radiol (1994) 1.48
Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med (2002) 1.47
Survival following cardiac transplantation--what are acceptable standards? West J Med (1987) 1.47
The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med (1969) 1.45
Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation (1991) 1.43
Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol (2000) 1.43
Multiple hormonal responses to graded exercise in relation to physical training. J Appl Physiol (1972) 1.42
Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway. J Biol Chem (1996) 1.42
Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation (1996) 1.41
Graft vascular disease in the great vessels and vasa vasorum. Hum Pathol (1993) 1.41
In situ hybridization studies for viral nucleic acids in heart and lung allograft biopsies. Am J Clin Pathol (1990) 1.41
Biosynthesis of collagen and other matrix proteins by articular cartilage in experimental osteoarthrosis. Biochem J (1980) 1.40
Inhibition of insulin secretion by infused epinephrine in rhesus monkeys. Endocrinology (1966) 1.39
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest (2001) 1.37
Echocardiographic recognition and implications of ventricular hypertrophic trabeculations and aberrant bands. Circulation (1984) 1.36
Whipple's disease presenting as aortic insufficiency. N Engl J Med (1981) 1.36
Urinary free-cortisol levels in posttraumatic stress disorder patients. J Nerv Ment Dis (1986) 1.35
Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med (1978) 1.34
The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant (1989) 1.34
Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med (1987) 1.34
Percutaneous transvenous endomyocardial biopsy. JAMA (1973) 1.33
Medicare-designated centers for cardiac transplantation. N Engl J Med (1987) 1.32